A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

British Journal of Haematology

Volumn 98, Issue 3, 1997, Pages 711-718

  Prentice, H G ^a   Hann, I M ^b   Herbrecht, R ^c   Aoun, M ^d   Kvaloy, S ^e   Catovsky, D ⁿ   Pinkerton, C R ^f,g   Schey, S A ^h   Jacobs, F ⁱ   Oakhill, A ^j   Stevens, R F ^k   Darbyshire, P J ^l   Gibson, B E S ^m  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c HÔPITAL CIVIL   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e Norwegian Inst for Cancer Research   (Norway)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ ERASME HOSPITAL   (Belgium)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^k ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^l BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^m ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

ⁿ NONE

more..

Author keywords

AmBisome; Amphotericin B; Fungal infection; Neutropenia; PUO

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; COLISTIN; LIPOSOME; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; SULFONAMIDE; TEICOPLANIN; VANCOMYCIN;

ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 9844239388     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.2473063.x     Document Type: Article

References (10)

1. Adler-Moore, J.P. (1994) AmBisome targeting to fungal infections. Bone Marrow Transplantation, 14, s3-s7.
2. Adler-Moore, J.P. & Profitt, R.T. (1993) Development, characterisation, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research, 3, 429-450.
3. de Marie, S., Janknegt, R. & Bakker-Woudenberg, I.A.J.M. (1994) Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Applied Chemistry, 33, 907-916.
4. EORTC International Antimicrobial Therapy Co-operative Group (1989) Empiric antifungal therapy in febrile granulocytopenia. American Journal of Medicine, 86, 668-672.
5. Fraser, I.S. & Denning, D.W. (1993) Empiric amphoterecin B therapy: the need for a reappraisal. Blood Reviews, 7, 208-214.
6. Goodwin, S.D., Cleary, J.D., Walawander, C.A., Taylor, J.W. & Grasela, T.H., Jr (1995) Pretreatment regimens for adverse events related to infusion of amphotericin B. Clinical Investigative Dermatology, 20, 755-761.
7. Janknegt, R., de Marie, S., Bakker-Woudenberg, I.A.J.M. & Crommelin, D.J.A. (1992) Liposomal and lipid formulations of amphotericin B. Clinical Pharmacokinetics, 4, 279-291.
8. Meunier, F., Prentice, H.G. & Ringden, O. (1991) Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. Journal of Applied Chemistry, 28. (Suppl. B), 83-91.
9. Pizzo, P.A., Robichaud, K.J., Gill, F.A. & Witebsky, F.G. (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged lever and granulocytopenia. American Journal of Medicine, 72, 101-111.
10. Profitt, R.T., Satorius, A., Chiang, S.M., Sullivan, L. & Adler-Moore, J.P. (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Applied Chemistry, 28, 49-61.